1. Scrip
  2. >>Business
  3. >>Deals

High Deal Valuations & Volumes Will Persist, Industry Dealmakers Predict

 
• By Jessica Merrill

Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.

Close up top view of young business people putting their hands together.
Industry leaders expect lots of partnering in 2021 • Source: Shutterstock

Industry business development leaders expect an active deal-making year in 2021 but that high valuations for biotech assets will continue to be a challenge for big pharmaceutical companies looking to fill their pipelines. Executives from AbbVie Inc., Amgen, Inc., AstraZeneca PLC, Genentech, Inc. and Boehringer Ingelheim GmbH discussed the business development landscape for pharma during a panel session at the Biocom Global Life Science Partnering Conference on 24 February.

The COVID-19 pandemic has thrown the industry a curveball on multiple fronts, but despite business disruptions caused by the global health crisis, industry has largely pivoted to virtual business development negotiations. While deal activity was overall lower in 2020, it rebounded in the second half of the year, and drug companies have lots of firepower to spend on deals going into the new year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

More from Business

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.